Show simple item record

dc.contributor.authorBurke, Luke K.
dc.contributor.authorOgunnowo-Bada, Emmanuel
dc.contributor.authorGeorgescu, Teodora
dc.contributor.authorCristiano, Claudia
dc.contributor.authorMartinez De Morentin, Pablo B.
dc.contributor.authorValencia-Torres, Lourdes
dc.contributor.authorD'Agostino, Giuseppe
dc.contributor.authorRiches, Christine
dc.contributor.authorHeeley, Nicholas
dc.contributor.authorRuan, Yue
dc.contributor.authorRubinstein, Marcelo
dc.contributor.authorLow, Malcolm J.
dc.contributor.authorMyers, Martin G.
dc.contributor.authorRochford, Justin J.
dc.contributor.authorEvans, Mark L.
dc.contributor.authorHeisler, Lora K.
dc.date.accessioned2018-01-09T11:33:06Z
dc.date.available2018-01-09T11:33:06Z
dc.date.issued2017-10-31
dc.identifier.citationBurke , L K , Ogunnowo-Bada , E , Georgescu , T , Cristiano , C , Martinez De Morentin , P B , Valencia-Torres , L , D'Agostino , G , Riches , C , Heeley , N , Ruan , Y , Rubinstein , M , Low , M J , Myers , M G , Rochford , J J , Evans , M L & Heisler , L K 2017 , ' Lorcaserin improves glycemic control via a melanocortin neurocircuit ' , Molecular Metabolism , vol. 6 , no. 10 , pp. 1092-1102 . https://doi.org/10.1016/j.molmet.2017.07.004en
dc.identifier.issn2212-8778
dc.identifier.otherPURE: 104833543
dc.identifier.otherPURE UUID: a9797ece-5b59-4a7c-83b6-d117a7593cc6
dc.identifier.otherScopus: 85028336606
dc.identifier.otherORCID: /0000-0002-5020-4939/work/53729084
dc.identifier.urihttp://hdl.handle.net/2164/9877
dc.descriptionAuthors wish to thank members of staff of the Medical Research Facility University of Aberdeen, Ms Raffaella Chianese, Ms Pat Bain, Dr Samuel Virtue and Dr Guenievre Roussel for technical assistance. Work was supported by the Wellcome Trust (LKH: WT098012, WT081713; LKH/LKB: 093566/Z/10/A; JJR/GD'A/PBMM: 100574/Z/12/Z), Diabetes UK (MLE: 13/0004680), Biotechnology and Biological Sciences Research Council (LKH: BB/K001418/1, BB/NO17838/1 and JJR: BB/K017772/1), the Medical Research Council (JJR: MR/L002620/1; LKH: MC/PC/15077; GD'A: MR/P009824/1), the Cambridge MRC Centre for Study of Obesity and Related Disorders (MRC-CORD) to LKH, MLE and LKB, European Commission (PBMM/LKH 660219-NeuroEE), Genomics/Transcriptomics Core Facilities, the Neuroscience Graduate Program, the National Institutes of Health (MJL: DK066604; MJL/MR: DK068400; MGM: DK056731) and the Marilyn H. Vincent Foundation to MGM.en
dc.format.extent11
dc.language.isoeng
dc.relation.ispartofMolecular Metabolismen
dc.rightsUnder a Creative Commons license https://creativecommons.org/licenses/by/4.0/en
dc.subject5-HT2c receptoren
dc.subjectType 2 diabetesen
dc.subjectHypothalamusen
dc.subjectLorcaserinen
dc.subjectPro-opiomelanocortin (POMC)en
dc.subjectMelanocortin4 receptor (Mc4r)en
dc.subjectR Medicine (General)en
dc.subjectWellcome Trusten
dc.subjectWT098012en
dc.subjectWT081713en
dc.subject093566/Z/10/Aen
dc.subject100574/Z/12/Zen
dc.subjectBiotechnology and Biological Sciences Research Council (BBSRC)en
dc.subjectBB/K001418/1en
dc.subjectBB/NO17838/1en
dc.subjectBB/K017772/1en
dc.subjectMedical Research Council (MRC)en
dc.subjectMR/L002620/1en
dc.subjectMC/PC/15077en
dc.subjectMR/P009824/1en
dc.subjectEuropean Commissionen
dc.subject660219-NeuroEEen
dc.subjectSupplementary Dataen
dc.subject.lccR1en
dc.titleLorcaserin improves glycemic control via a melanocortin neurocircuiten
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Rowett Instituteen
dc.contributor.institutionUniversity of Aberdeen.Medical Educationen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Clinical Medicineen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1016/j.molmet.2017.07.004


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record